How many drugs treat Deep vein thrombosis?

Drug Landscape tracks 3 marketed treatments for Deep vein thrombosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/deep-vein-thrombosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Deep vein thrombosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep vein thrombosis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Deep vein thrombosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Pradaxa	dabigatran-etexilate	Boehringer Ingelheim	Direct thrombin inhibitor	Thrombin (serine protease)	2010-01-01
Dabigatran etexilate (DE)	dabigatran-etexilate-de	Pfizer Inc.	Dabigatran etexilate (DE) as oral capsule	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 1 drug in Deep vein thrombosis
Generic (originally Boehringer Ingelheim) · 1 drug in Deep vein thrombosis
Pfizer Inc. · 1 drug in Deep vein thrombosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Deep vein thrombosis:

Cite this brief

Drug Landscape (2026). Deep vein thrombosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/deep-vein-thrombosis. Accessed 2026-06-10.

Deep vein thrombosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing